NAS:OPNT (USA)
Business Description
Opiant Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401
Compare
Compare
Traded in other countries / regions
8OP.Germany
•
OPNT.USA
Description
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.49 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | -3.98 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.45 | |||||
| Beneish M-Score | -3.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15 | |||||
| 3-Year Book Growth Rate | 29.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.25 | |||||
| 9-Day RSI | 68.81 | |||||
| 14-Day RSI | 57.98 | |||||
| 6-1 Month Momentum % | -53.21 | |||||
| 12-1 Month Momentum % | -26.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.72 | |||||
| Quick Ratio | 8.72 | |||||
| Cash Ratio | 7.49 | |||||
| Days Sales Outstanding | 91.84 | |||||
| Days Payable | 149.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.5 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.94 | |||||
| Operating Margin % | -11.16 | |||||
| Net Margin % | -16.42 | |||||
| ROE % | -15.96 | |||||
| ROA % | -9.89 | |||||
| ROIC % | -55.21 | |||||
| ROC (Joel Greenblatt) % | -60.82 | |||||
| ROCE % | -7.48 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.87 | |||||
| PB Ratio | 1.54 | |||||
| Price-to-Tangible-Book | 1.54 | |||||
| EV-to-EBIT | -5.64 | |||||
| EV-to-EBITDA | -6.64 | |||||
| EV-to-Revenue | 0.63 | |||||
| EV-to-Forward-Revenue | 1.31 | |||||
| EV-to-FCF | -12.68 | |||||
| Price-to-Projected-FCF | 1.32 | |||||
| Price-to-Net-Current-Asset-Value | 1.59 | |||||
| Price-to-Net-Cash | 2.03 | |||||
| Earnings Yield (Greenblatt) % | -17.72 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:OPNT
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 38.584 | ||
| EPS (TTM) ($) | -1.46 | ||
| Beta | 0.72 | ||
| Volatility % | 82.94 | ||
| 14-Day RSI | 57.98 | ||
| 14-Day ATR ($) | 0.781178 | ||
| 20-Day SMA ($) | 10.838 | ||
| 12-1 Month Momentum % | -26.5 | ||
| 52-Week Range ($) | 7.34 - 37.7114 | ||
| Shares Outstanding (Mil) | 5.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Opiant Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||